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ABSTRACT OF THE THESIS
CALCULATIONS ON THE END-GROUP CONFORMATIONAL BARRIER IN
CAROTENOIDS AND A STUDY OF THE BIOAVAILABILITY OF
XANTHOPHYLL ESTERS IN HUMANS
by
Francesca Alvarez-Calderon

Florida International University, 2007
Miami, Florida
Professor John T. Landrum, Major Professor
The present study measures the increase in serum carotenoid concentration in 30
healthy individuals after supplementation with a low dose xanthophyll ester (3 and 6 mg
of lutein equivalent/per day) when compared to a placebo. Serum levels of carotenoids
were measured using HPLC and showed an increase in the concentration of lutein,
zeaxanthin and four lutein metabolites proportional to dose.
In order to further assess the importance of the end-group structure in carotenoids
we have investigated the influence of the end-group type and functionality on the
conformational energy barrier. We used the density functional method implemented on
GAUSSIAN 98 to calculate the conformational energy curves for rotation of the P-ring or
the E-ring relative to short polyene chains around the C6-C7 single bond. A large barrier
is observed for the interconversion of conformers in the E-rings (8 kcal/mol) when
compared to beta rings (2.3-3 kcal/mol).
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CHAPTER I:

INTRODUCTION

Carotenoids are naturally abundant pigments produced exclusively by plants,
algae, bacteria and some species of fungi. [1] Animals cannot synthesize carotenoids and
thus they rely on their diet for absorption. Carotenoids are found in significant quantities
in the human body where their roles have been investigated. Several epidemiological
studies have suggested a direct relation between carotenoids and improved health but the
mechanism of action is yet to be proven. Only specific carotenoids are absorbed from the
diet and they are selectively accumulated in certain tissues. Surprisingly, minor structural
differences between carotenoids define their function and reactivity while not
significantly affecting other physical properties such as solubility, polarity, oxidation
potential, electronic states, etc. The importance of these structural differences between
carotenoids and the mechanism by which carotenoids exert their effect on human health
remains incompletely understood. In the present study, the effect of the structural
differences in carotenoids were investigated by measuring the energy required for the
rotation of the end-groups on carotenoids. Also, the present study monitored the
bioavailability of carotenoids in subjects given low doses of a xanthophyll ester
supplement.

1.1.

Structure and nomenclature
Carotenoids, including the carotenes, and their oxygenated derivatives,

xanthophylls, consisting of eight isoprenoid units joined in such a manner that the

1

arrangement of isoprenoid units is reversed at the center of the molecule so that the two
central methyl groups are in a 1,6-positional relationship and the remaining non-terminal
methyl groups are in a 1,5-positional relationship. [2] All carotenoids may be formally
derived from the acyclic C40 H5 6 structure, figure 1, having a long central chain of
conjugated double bonds. Due to the presence of the conjugated double bonds,
carotenoids can undergo isomerization to cis carotenoids, commonly found in nature. [3]

Figure 1. Structure of lycopene

The name of a specific carotenoid is constructed by adding two greek letters as

prefixes to the stem name carotene, following the rules given by IUPAC. [4] The
prefixes correspond to the end-group designation in carotenoids.
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Figure 2. End-group designation

The difference in the position of a single double bond distinguishes between

and E-rings. In

p-rings,

-

the double bond occurs between C5-C6 extending the conjugation

of the

it system into the ring, while in c-rings, the double bond occurs between C4-C5,

where it is isolated from the n-system of the polyene chain, figure 3.
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Figure 3. Structural differences between (p- and s-rings

1.2.

Natural Occurrence
Zeaxanthin has two P-ionone rings each bearing a hydroxyl group attached at

carbon 3 or 3'. The most common form of zeaxanthin contains both hydroxyl groups in
the R configuration, but zeaxanthin, with its two stereocenters, can exist as three naturally
occurring stereoisomers, figure 4. The principal stereoisomer of zeaxanthin is (3R,3'R)1,p-caroten-3,3'-diol which is abundant in nature especially in egg yolk, orange, pepper,

kiwi, grapes, spinach and various other fruits and vegetables. [5] Zeaxanthin also
accumulates in human serum and tissues including the human macula. [6, 7]

(3R,3'S)-

(3,(-caroten-3,3'-diol (meso-zeaxanthin) is also present in the human macula [6, 7], in
shrimp (Paratyacompressa compressa) and in several species of fish (Oncorhynchus
keta, Seriola quinqueraduata,Micropterussalmoides, Tilapia nilotica [8], Salmo salar

and Salmo gairdneri[9]). In addition, (3S,3'S)-p3-caroten-3,3'-diol is found in the
same species of fish as meso-zeaxanthin. [8, 9]

3

HOH

Zeaxanthin, (3R,3'R)- ,(3-caroten-3,3'-diol

HOgO

Meso-zeaxanthin, (3R,3'S)-s,[3-caroten-3,3'-diol

(3S,3'S)-1,(3-caroten-3,3'-diol
Figure 4. Stereoisomers of zeaxanthin

Lutein, a constitutional isomer of zeaxanthin in which one of the

P-ionone

ring is

replaced by an E-ionone ring, contains three stereocenters and can exists in eight
stereomeric forms, figure 5. Of these, only five have been identified in nature (labeled
with an asterisck in figure 5). The principal natural stereoisomer of lutein is
(3R,3'R,6'R)-3,E-carotene-3,3'-diol which is abundant in plants (maize, spinach, etc.
[5]), egg yolk [10], in the plumage and beak of birds [11] and is accumulated in several

animal tissues such as serum, macular region of the human eye [12], and adipose tissue

[13]. 3'-epilutein or calthaxanthin [(3R,3'S,6'R)-3,E-carotene-3,3'-diol] was identified in
the petals of marsh marigold (Caltha palustris)[14, 15], the petals of Rosa gallica [16],
the integuments of goldfish (Carassiusauratus) [17, 18] and of several other fish species
[19]. The term epilutein describes the relation between (3R,3'R,6'R)-lutein and the
individual diastereomers of lutein.
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HO

(3R,3'R,6'R)-s,E-caroten-3,3'-diol*

OH

(3R,3'S,6'R)-1,E-caroten-3,3'-diol*
,OH

HO

(3R,3'R,6'S)-,E-caroten-3,3'-diol*

HOH

(3R,3'S,6'S)-(,E-caroten-3,3'-diol*

HOOH

(3S,3'R,6'R)-P,E-caroten-3,3'-diol

H

OH

(3 S,3' R,6'S)-E-caroten-3,3'-diol*
,OH

(3S,3'S,6'R)-(3,E-caroten-3,3'-diol

HO

OH

(3 S,3' S,6' S)-P,E-caroten-3,3' -diol
Figure 5. Stereoisomers of lutein

6'-epilutein, (3R,3'R,6'S)- ,E-carotene-3,3'-diol, and 3',6'-epilutein,
(3R,3'S,6'S)-p3,E-carotene-3,3'-diol, have been identified in the integuments of several
fish species: Branchiostegusjaponicusjaponicus, Inimicusjaponiicus,Platycephalus
indicus and several others [20], and in eggs of dolphin-fish (Coryphaena hippurus) and

flying fish (Prognichthysagoo) [21]. 3,6'-epilutein or (3S,3'R,6'S)-,E-carotene-3,3'diol have been identified in the integuments of Podothecussachi and Epinephelusfario
[20]. With the exception of 3,6'-epilutein, all naturally found lutein diastereomers have
the stereocenter on carbon 3 in the R configuration.

1.3.

Ultraviolet-visible spectra of carotenoids
Carotenoids absorb light strongly and exhibit intense absorption bands in the

visible and ultraviolet region due to their extensive conjugated double bond system.
Systems with multiple conjugated double bonds often show several peaks in their
absorption spectra due to the electronic transitions between different vibrational energy
levels. The UV-visible spectra of carotenoids provide valuable information for structural
characterization and quantitative analysis. [1] The position of the wavelength of
maximum absorbance

(Xmax),

the spectral shape and the intensity of absorption provides

crucial information. The UV-spectra of carotenoids show three overlapping absorption
bands, figure 6. The resolution of the peaks depends on the structure of the carotenoid.
The fine structure can be described numerically by the ratio, %III/II, where III is the
intensity of the longest wavelength absorption band and II is the intensity of the middle
band, measured from the minimum between the two peaks, figure 6. Thus, the presence

6

of (3- or

E-end

group rings can usually be determined from the UV-spectra of the

carotenoids.

1.0
~~~

0.8

II

III

0.6
0.4
0.2

0.0
300.0 400.0

500.0

600.0

Wavelength (nm)

Figure 6. UV/Visible spectra of lutein showing band II and band III

The loss of the interaction between the double bond and the polyene J-system
resulting from the interconversion between

Ip- and E-rings results in a consistent 5 nm

shift towards the blue region (hypsochromic shift) in the absorption spectra and causes an
increase in the overlap of the absorption bands, especially between band II and III. The
structure and UV-spectra of zeaxanthin [(3R,3'R)-(3, -carotene-3,3'-diol], lutein

[(3R,3'R,6'R)-(3,E-carotene-3,3'-diol] and lactucaxanthin [(3R,6R,3'R,6'R)-E,E-carotene3,3'-diol] demonstrate the effect the extent of conjugation have on the UV-spectra,

figures 7 and 8.

7

In the xanthophyll series, zeaxanthin has the greatest conjugation with its two (3ionone rings, followed by lutein with a j3-ionone ring and an c-ionone ring and
lactucaxanhin with two E-ionone rings.

OH

H

Zeaxanthin

[(3R,3'R)-P,1-carotene-3,3'-diol]

HO

Lutein

[(3R,3'R,6'R)-3,E-carotene-3,3'-diol]

Lactucaxanthin

[(3R,6R,3'R,6'R)-F,E-carotene-3,3'-diol]
Figure 7. Structure of lutein, zeaxanthin and lactucaxanthin

The wavelength of maximum absorbance as measured in ethanol for this series is

450 [22], 445 and 439 [23] nm, respectively. A consistent 5 nm shift is observed with
decrease conjugation. The increase in overlap between the absorption bands results in a
%II/III of 25, 60 and

95%,

respectively. A similar trend is observed for the carotene

series which includes t3-carotene [1,p3-carotene], a-carotene [(6'R)-(3,E-carotene] and E-

carotene [(6R,6'R)-E,E-carotene], for which

Xmax

is 450, 445 and 441 nm and %II/III is

15-25 (depending on the solvent), 55 and 89%, respectively.
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Zeaxanthin
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Figure 8. UV-Spectra of zeaxanthin, lutein and lactucaxanthin

1.4.

Biosynthetic Pathway
C 40 carotenoids are made in thousands of plant and microbial species, starting

with the synthase-catalyzed condensation of two molecules of geranylgeranyl

diphosphate (C2 0PP) to form phytoene, generally the all-trans isomer of phytoene. [24]
Phytoene undergoes several levels and types of modification leading to the majority of
the known carotenoids, figure 9. The initial C 40 condensation products are
dehydrogenated in a stepwise manner by desaturase enzymes leading to the formation of
lycopene. [25] In many organisms, desaturation is followed by cyclization, catalyzed by
a (3- or c-cyclase and leading to carotenoids with one or two cyclized ends. [26] A
variety of further enzyme-catalyzed transformations that can include ketolation,
hydroxylation, glycosylation and oxidative cleavage, act on substrates derived from the

9

C 30 or C 4O backbones to produce the more than 700 known carotenoids. [27] Several of
the xanthophylls bear hydroxyl groups on their end-rings which may be esterified with
fatty acids in plant cells resulting in mono- and diacylated derivatives, further modifying
the carotenoids. [28]

OPP

geranylgeranyl diphosphate
(C 2oPP)

15Z)-phytoene

desaturation

desaturation

P-cyclization

hydroxylation
ketolation
glycosylation
esterification
Figure 9. General carotenoid biosynthetic pathways
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neurosporene

lycopene

0,P-carotene

1.5.

Carotenoid esterification
Esterification occurs in most plant tissues, flower petals accumulate xanthophylls

in their esterified form. Six different lutein diesters, specifically lauroylmyristoyl-lutein,
dimyristoyl-lutein, myristoylpalmitoyl-lutein, dipalmitoyl-lutein, palmitoylstearoyl-lutein
and distearoyl-lutein have been isolated from extracts of native marigold flowers. [28]
The major lutein ester found in marigold flowers is dipalmtoyl-lutein, figure 10.

Esterification allows the plant metabolic system to increase the liposolubility of
xanthophylls, which is associated with plant senescence and fruit ripening. [29] Lutein
diesters and other xanthophyll diesters occur in the carotenoid fractions of several fruits
and vegetables including apple, apricot, avocado, chili, clementines, mango, orange,
papaya, peach, yellow and red peppers, potatoes [29], kiwano, cape gooseberry and
pumpkin in which the lutein diesters dimyristoyl-lutein, myristoylpalmitoyl-lutein and
dipalmitoyl-lutein account for 2-5% of the total carotenoid content. [28]

Figure 10. Structure of dipalmitoyl-lutein
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Esterification does not change the chromophore properties of the carotenoids but
it does increase the liposolubility of xanthophylls. Their lipophilic nature helps to
accumulate xanthophylls in lipid-rich plastoglobules, increasing colorant capacity and
making fruits and flowers more attractive to animals that disseminate seeds and pollen.
[30] When polyunsaturated fatty acids are esterified to xanthophylls, the antioxidant

activity is diminished because the fatty acids are able to propagate the radical chain
increasing the pro-oxidant reactions synergistically. [31]

1.6.

Function in plants
Carotenoids are involved in photosynthesis as light-harvesting pigments and act to

prevent the photochemical formation of singlet oxygen. [32] Carotenoids absorb light in

the wavelength region where chlorophyll only absorbs weakly improving the efficiency
of photosynthesis. Plants also contain several varieties of carotenoids that are involved in
light energy dissipation, known as non-photochemical quenching, regulated by the

xanthophyll cycle. [33] The xanthophyll cycle protects the thylakoid membranes against
lipid peroxidation. [34] Within the thylakoid membranes, carotenoids are bound to
specific carotenoid-binding complexes of the two photosystems, PSI is enriched in

carotene while PSII is enriched in lutein. [35]

1.7.

Human metabolism
Most fruits and vegetables contain both free carotenoids and their fatty acid

derivatives. In the case of esterified carotenoids, these are hydrolyzed before being
absorbed. The specific enzymes involved in the gastric hydrolyzation of ester
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p-

carotenoids is unknown.[36] Esterified xanthophylls have been found in human serum
and peripheral tissues in very low concentrations, less than 3 % of the total serum lutein
concentration, and only in individuals supplemented for an extended period of time with

a high dosage xanthophyll ester supplement (15 mg/day for 4 months). [37]
Carotenoids are lipid soluble, thus they follow the same absorption mechanism as
most other fatty minor components. Dietary carotenoids are released from the food

matrix and incorporated into mixed micelles composed of bile salts.[38] The lipophilic
components from the diet are absorbed by the enterocytes, packed into chylomicrons in
the intestines and transported to the liver where they are packed into other

lipoproteins. [39]

1.8.

Carotenoids and human health
Studies have shown that an increase in the consumption of carotenoids may be

beneficial in preventing human diseases such as age-related macular degeneration (AMD)
[40], cataracts [41], cardiovascular disease [42], cancer [43, 44] and other chronic disease

[45]. Carotenoids, specifically

c-carotene,

f3-carotene and

B-cryptoxanthin,

are the major

dietary source of vitamin A. [46] Carotenoids might help maintain cell-to-cell
communication by reducing the damage caused by reactive oxygen species to cell
membranes and their associated receptors and modulating immune cell function by
influencing the activity of redox-sensitive transcription factors and the production of
cytokines and prostaglandins.[47] Carotenoids may also act as photoprotectors against
harmful UV radiation and to quench singlet oxygen. [48]
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1.9.

Serum Carotenoids
The major serum carotenoids are shown in figure 11.

Lutein [(3R,3'R,6'R)-,E-carotene-3,3 '-diol]

HO

Zeaxanthin [(3R,3'R)-sp3-carotene-3,3 '-diol]

Lycopene [y,y-Carotene]

[-Cryptoxanthin [(3R)-(3, -carotene-3-ol]

HO

a-Cryptoxanthin [(3R,6'R)-B 3-carotene-3-ol]

P-Carotene [s3,p-Carotene]

c-Carotene [(6'R)-3,E-carotene]
Figure 11. Structure of serum carotenoids
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The human diet comprises numerous carotenoids, but only 34 carotenoids,
including 13 geometrical isomers and eight metabolites, have been identified in human
serum and/or breast milk.[49] The major carotenoids present in serum include
carotene, a-carotene, a-cryptoxanthin,

pi-

P-cryptoxanthin, lycopene, lutein and zeaxanthin,

figure 11, but the specific profile is dependant on the individual diet. These carotenoids
account for 90% of the plasma carotenoid pool in serum. [50] Other tissues, specifically
the liver, adipose tissue, colon, pancreas, prostate, macula and skin, accumulate
significant amounts of these carotenoids. [51, 52]
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CHAPTER II:
CALCULATIONS ON THE END-GROUP CONFORMATIONAL BARRIER IN
CAROTENOIDS

2.1.

Overview
Extensive research has been performed on the significance, structure and

metabolism of biologically important carotenoids both in vivo and in vitro. But little
research have been devoted to address the importance that conformation may have on
these carotenoids within membranes, or their structure within protein binding pockets of

proteins which are specific carotenoid binders. [53-55]
The correlation between dietary carotenoids and the carotenoids routinely found
in extracts from human serum/plasma reveals that only selected carotenoids make their
way into the human bloodstream, and there is further selectivity in the uptake of
carotenoids into a number of human tissues, notably the retina. The presence of these
carotenoids in human tissues requires that they be effectively absorbed from the diet and
selectively transported. This is now recognized to involve a variety of carotenoid binding
proteins. Carotenoids are lipophyllic and are soluble and accumulate in cellular
membranes. The behavior of carotenoids in biological membranes is related to their
structure, in particular to their orientation within the membrane. The xanthophylls, with
their polar end-groups, may span the membranes and anchor with the polar heads of
phospholipids while carotenes may be embedded within the membranes. Polar
carotenoids are present in thylakoid membranes where they regulate membrane fluidity.
Also, certain carotenoids disrupt the geometry of the binding pockets in proteins.
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j3-carotene is bound and cleaved in vivo by 3-carotene 15,15'-monooxygenase,
whereas the xanthophylls and other oxygenated derivatives are not. The xanthophylls,
zeaxanthin and lutein, support the light harvesting complex assembly while
lactucaxanthin does not which suggests that the three dimensional geometry of the endgroups in these carotenoids is a key to their incorporation in the protein assembly. [56]
Differences in the behavior of xanthophylls in both membranes and proteins can be seen
and can be attributed to difference in their end group structures. The presence of a

P-end

group or an E-end groups in carotenoids would appear to favor the ability of the
carotenoid to adopt specific orientations in membranes. The conformational barriers
between the possible geometric conformations will dictate the energy required for the
carotenoid to adopt one specific orientation as opposed to another.

P-ionone

rings, as those found in zeaxanthin and

p-carotene,

exhibit near or quasi

co-planarity between the polyene chain and the plane of the ring. It is widely accepted
that the

p-ionone

rings prefer a conformation in which the double bond in the

cyclohexene ring is in a quasi-S-cis geometry relative to the polyene chain. In E-rings,

due to the presence of a stereocenter at C6', this co-planarity is disrupted. The change in
hybridization at C6 from sp2 to spa causes a considerable increase in the crowding
between the methyl groups on C1 and C5 and the vinylic hydrogens, H7 and H8. The
bent E-ionone ring in lutein is visible in the 3D-structure of the shortened apocarotenes,
13-apo-p-carotene and 13-apo-E-carotene, figure 12.
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13-apo-p-carotene

13-apo-E-carotene

Figure 12. 3D-Structure of 13-apo-p-carotene and 13-apo-E-carotene

The principal aim of this study is to model several biologically important
carotenoids specifically

B-carotene

[3,p-carotene], lutein [(3R,3'R,6'R)-3,c-caroten-3,3'-

diol], zeaxanthin [(3R,3'R)-3,3-caroten-3,3'-diol], oxo-lutein [(3R,6'R)-3-hydroxy-P,Ecaroten-3'-one] and oxo-zeaxanthin [f,(3-caroten-3,3'-dione] to discover their preferred
orientation end-group ring in space relative to the polyene chain. The carotenoids
investigated are symmetrical with respect to the C 15-C15' single bond, thus a shortened
model composed of apocarotenals was used to increase the efficiency of the
computations. Secondly, determination of the effect that chain length in the shortened
model has on the C6-C7 rotational barrier of carotenoids by varying the chain length of
several structures. Thirdly, determine the effect of chain termination on the C6-C7
rotational barrier, specifically the presence of an aldehyde functional group at C15.
Finally, determine the effects of substituents present in the cyclohexene ring on the C6C7 rotational barrier and the presence of different stereoisomers of those carotenoids.
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2.2.

Research methodology

2.2.1.

Z-matrix input [571
In this study, a z-matrix was constructed starting from an arbitrarily selected

atom, labeled 1 in figure 13. The z-matrix specifies the locations of and bonds between
atoms using bond lengths (angstroms), bond angles and dihedral (torsion) angles
(degrees).

35

2

34

1 33

21

1816

13

31

337

171

39

20
3

361

26

28

29

22

2622

Figure 13. 3D-Structure of 1 1-apo-13-carotene showing selected bond lengths, bond
angles and dihedral angles.
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The molecule specifications are given by the charge and spin multiplicity as two
integers directly above the first line of the matrix. The spin multiplicity is calculated
from the equation 2S + 1, where S is the total spin for the molecule. Each unpaired
electron contributes +1/2 to S thus a system with no unpaired electrons (singlet) has a
spin multiplicity of 1 and a system with one unpaired electrons (doublet) has a spin
multiplicity of 2. The first line of the Z-matrix consists solely of the atomic symbol for

the starting atom in the molecule, table 1.

Table 1. Z-matrix for 1-apo-s-carotene

#N b3lyp/6-31g* opt=(z-matrix)
01
c
cl rl
c2r2 1 al
c3 r3 2 a2 1 dl
c 4 r4 3 a3 2 d2
c5 r54 a43 d3
c6r65a54d4
c7 r76 a65 d5
c 8 r8 7 a7 6 d6

h 13 r18 1 a17 2 d16
h 13 r19 1 a18 2 d17
h 13 r20 1 a192 d18
h2r213a204d19
h 2 r22 3 a21 4 d20
h3 r23 4 a225 d21
h3 r244 a23 5 d22
h4r25 3 a242 d23
h4r263 a252 d24
h 14r275a264d25
h 14r28 5 a274 d26
h 14r295 a284 d27

c9r98 a8 7 d7
c10r109a98d8

h 7 r30 8 a29 9 d28
h8r319a3010d29

clrll2a103d9
c 1 r122all 3d10

h15r329a3110d30
h 15r339a3210d31

c 5 r13 4 a12 3 d12

h 15r349a33 10d32

c9r14 10a13 11 d12
h 12 r15 1 a14 2 d13
h 12 r16 1 a15 2 d14
h 12r17 1 a162d15

h
h
h
h

10 r35
11 r36
11 r37
11 r38

9 a34 8 d33
10 a35 9 d34
10 a36 9 d35
10a379d36

The second input line includes the atomic symbol of the second atom, the label of
the atom it is bonded to (the first atom) and the label for the bond length given by the

20

letter r followed by an integer, in that order. The items are separated by spaces. The
third input line locates the molecules position in the xy-plane. This input line will
include the atomic symbol for the third atom directly attached to one of the previously
specified atoms, the label for the atom it is bonded to and the bond length, the label of the
other atom forming the bond angle and the label for the bond angle given by the letter a
followed by an integer.

The position of all subsequent atoms are specified by its atomic symbol; an atom
it is bonded to and the label for the bond length (r); a third atom bonded to it and the
value of the resulting bond angle (a); and a forth atom bonded to either end of the
previous chain and the value of the dihedral angle formed by the four atoms (d).
Dihedral angles describe the angle the fourth atom makes with respect to the plane
defined by the first three atoms. Dihedral angles are easy visualized using Newman
projections, figure 14. Positive dihedral angles correspond to clockwise rotation in the
Newman projection.

+D

Figure 14. Newman projection for C1-C2-C3-C4 indicating the sign convention used

In a separate section below the complete z-matrix, the initial bond lengths, bond
angles and dihedral angles are specified in the format rl= followed by the optimized
value. A blank line separates the two sections. The initial optimized parameters were
obtained from Chemdraw after energy minimization.
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2.2.2.

Computational Methods
The Becke 3-parameter density functional method using the Lee-Yang and Parr

Correlation Functional (B3lyp) implemented on Gaussian 98 will be used to calculate the
conformational energy curve for rotation of the carotenoid ring relative to a short polyene
chain around the C6-C7 single bond as defined by its dihedral angle. It was be
computationally inefficient to calculate the conformational barrier for the entire
carotenoid structure so a model with a shortened polyene chain was used. Geometry

optimization was initially performed for all degrees of freedom, including bond lengths,
bond angles and dihedral angles. The dihedral angle between C5-C6-C7-C8 was fixed at
15° intervals from -180* to 1800 while all other parameters were allowed to vary.

2.3.

Results
The conformational energy barrier for the rotation of the end-ionone group in

carotenoids was constructed from the relative energies obtained from Gaussian 98 at 300
intervals. The dihedral angle at which the most stable conformation occurs is also given
by Gaussian.

2.3.1.

Chain length
The effect of chain length on the conformational barrier of carotenoids was

investigated by the use of three structures varying in chain length, figure 15. The
conformational barrier for 11-apo-j3-carotene, 13-apo-p-carotene and 15-apo-p-carotene
is shown on figure 16.
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11-apo-p-carotene

13-apo-p-carotene

15-apo-p-carotene

Figure 15. Structure of 11-apo-p-carotene (O), 13-apo-p-carotene (I) and 15-apo-p-

carotene (A)
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Figure 16. Conformational barrier of 11-apo-p-carotene (O), 13-apo-p-carotene (L) and
15-apo-p-carotene (A)

The most stable conformation for the three apocarotenes occur within 10 of each

other, for 11-apo-B-carotene at 49.20, for 13-apo-p-carotene at 48.20 and for 15-apo-p-
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carotene at 47.80. The increase in length and conjugation of the polyene chain decreases
the dihedral angle at which the most stable conformer occurs. Similarly, the position of
the second most stable conformation is also decreased in the series and occurs within 3.50
of each other, at -51.4, -49.2 and -47.9°, respectively. Symmetry is observed in the
conformational barrier with respect to the s-cis conformation. Rotation of approximately
500 clockwise or counterclockwise achieves two minima with an energy difference of
0.35 kcal/mol for 11-apo-0-carotene, 0.33 kcal/mol for 13-apo-p-carotene and 0.34
kcal/mol for 15-apo-p-carotene. The same symmetry is not observed with respect to the
s-trans conformation, in which only one local minimum in the potential energy is

observed at 165.6, 167.8 and 165.00, respectively.
The increase in chain length does not greatly affect the position of the minima and
maxima nor does it affects the overall conformational barrier. The energy difference
between the most stable and the second most stable structures is nearly constant at 0.33-

0.35 kcal/mol. The overall conformational barrier is slightly reduced from 3.25 kcal/mol
to 3.18 kcal/mol for 13-apo-p-carotene and 3.16 kcal/mol for 15-apo-o-carotene. A
distinguishable shoulder is observed for all structures at approximately -110° (quasi strans conformation). The cyclohexene ring is not planar and can adopt several ring
conformations, whereas the nearly twisted chair conformation is the most stable. Of the
two possible twist chair conformations, figure 17, the apo-p-carotenes adopt
conformation II more readily.
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II

I
Figure 17. Twist-chair conformations possible for

P-ionone rings

The ring puckering disrupts the quasi-s-transconformation only in the (-)-

dihedral direction, causing the shoulder in the energy barrier observed in figure 16. In
the (+)-dihedral direction carbon 1 is directed away from the polyene chain which
prevents this steric distortion and allows a relative minimum to occur. In figure 12, the
most stable conformation for the

2.3.2.

P-ring is

observed.

Chain Termination
The effect of chain termination on the conformational barrier was investigated by

comparing the energy diagram of 15-apo-p-carotene to that of 15-apo-P-carotenal. 15apo-p-carotenal is commonly known as retinal, a precursor of vitamin A. Figure 18
shows the structure of 15-apo-o-carotenal and figure 19 the conformational barrier for
15-apo-p-carotenal along with that of 15-apo-p-carotene for comparison.

I~

Figure 18. Structure of 15-apo-p-carotenal (0)
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Figure 19. Conformational barrier of 15-apo-p-carotene (A) and 15-apo-p-carotenal (L)

The change in termination at carbon 15 insignificantly reduces the energy

difference between the most stable and the second most stable conformation by 0.07
kcal/mol. The overall shape of the conformational barrier was considerably affected.
The 15-apo-p-carotenal conformer with a dihedral angle of 167.80 was stabilized by the
variation in termination. The most stable conformation occurs at a dihedral angle of
47.80 for 15-apo-p-carotene and at 49.60 for 15-apo-p-carotenal and the second most
stable conformation occurs at -47.9 and -45.90, respectively. The overall conformational
barrier was reduced from 3.16 to 3.06 kcal/mol. The shoulder in the conformational
barrier is more pronounced in the apocarotenal than in the apocarotene. The changes in
the conformational barrier, even though they are subtle, indicate a weak electronic
stabilization of the pi system of the polyene chain by the carbonyl functional group.
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2.3.3.

Functional groups
The combined effect of two functional groups, the ring hydroxyl and polyene

terminating carbonyl group, on the conformational energy barrier was investigated by
comparing the barrier of several (3- and £-rings shown in figure 20.

P-ionone
\

series
15-apo-p-carotenal

\

\

\

1

(3R)-hydroxy-15-apo-p-carotenal

0

HO

3-oxo-l5-apo-p-carotenal

0

E-ionone series

V

A

\

\

(6R)- 13 -apo- E-carotene

\

\

,

\

(3R,6R)-3-hydroxy-l5-apo-E°carotenal

\\

\ \

\,°(6R)-3-oxo-l5-apo-E-carotenal

\

0

Figure 20. Structure of P-series: 15-apo-p-carotenal (O), (3R)-hydroxy-5-apo-Pcarotenal (LI) and 3-oxo- 1 5-apo-p-carotenal (+); and E-series: (6R)-13-apo-E-carotene
(O), (3R,6R)-3-hydroxy-15-apo-c-carotenal (A) and (6R)-3-oxo-15-apo-c-carotenal (X)
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Figure 21 shows the conformational barrier for the

p-ionone

ring series including

that of 15-apo-p-carotenal, (3R)-hydroxy-15-apo-( -carotenal and 3-oxo-15-apo-p-

carotenal and figure 22 shows the conformational barrier for the E-ionone ring series
including that of (6R)-13-apo-E-carotene, (3R,6R)-3-hydroxy-15-apo-s-carotenal and
(6R)-3-oxo-15-apo-r-carotenal.

In the E-ionone ring series, the conformational barrier of

(6R)-13-apo-E-carotene was used for comparison. It was previously established that
lengthening and changing the termination on the polyene chain does not significantly
affect the conformational barrier.
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Figure 21. Conformational barrier of 15-apo-p-carotenal (O), (3R)-hydroxy-15-apo-P-

carotenal (L) and 3-oxo-15-apo-p-carotenal (+)
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Figure 22. Conformational barrier of (6R)-13-apo-e-carotene (O), (3R,6R)-3-hydroxy15-apo-e-carotenal (A) and (6R)-3-oxo- 15-apo-e-carotenal (X)

The addition of a hydroxyl group at carbon 3 in the

s-ionone ring does not greatly

influence the overall shape of the conformational energy curve. The position of the
minima in (3R)-hydroxy-apo-p-carotenal occurs at 46.70 for the most stable structure and
at -47.4° for the second most stable conformation. The energy difference among them
was 0.24 kcal/mol, only 0.03 kcal/mol lower than the energy difference for the two
minima in 15-apo-p-carotenal. The overall conformational barrier was 3.18 kcal/mol,
slightly but not significantly larger than that for 15-apo-p-carotenal (3.06 kcal/mol). The
conformational energy barrier for zeaxanthin was modeled by the conformational barrier
of (3R)-hydroxy-apo-p-carotenal.
The conformational barrier for (6R)-3-oxo-l5-apo-p-carotenal shows a similar
conformational barrier to that observed for all other beta-ring carotenoids modeled. Two
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minima are observed at 47.3* and -49.8° separated by 0.03 kcal/mol. The small energy
difference between the most stable and second most stable structure indicates the
molecule adopts both conformers readily. The change in hybridization at carbon 3 from
spa to sp 2 situates the substituent planar with respect to the ring, reducing the steric
interaction with the polyene chain. The overall conformational barrier for (6R)-3-oxo15-apo-p-carotenal was 3.40 kcal/mol, comparable to other apo-3-carotenals analyzed.
The quasi-s-transconformation in (6R)-3-oxo-15-apo-p-carotenal is higher in energy
than in the other

P-ionone

structures, possible due to the conformational limitations as a

result of the change in hybridization.
The conformational barrier for (3R,6R)-3-hydroxy-l5-apo-E-carotenal shows a
minimum at 113.30 and a second minimum at -23.3°, only 0.92 kcal/mol in energy
higher. Both (6R)-13-apo-E-carotene and (6R)-3-oxo-15-apo-E-carotenal show a
significant energy difference between the two most stable structures of 3.05 and 3.06
kcal/mol, respectively. In contrast with these two structures, (3R,6R)-3-hydroxy-15-apo-

F-carotenal readily adopts both conformations.

The conformational barrier for 3-oxo-15-

apo-E-carotenal showed two minima at 120.3 and -45.6 separated by 3.06 kcal/mol. The
position of the minima was in agreement with other apo-E-carotenals analyzed. The

overall conformational barrier for (6R)-13-apo-E-carotene, (3R,6R)-3-hydroxy- 1 5-apo-Ecarotenal and (6R)-3-oxo-15-apo-F-carotenal was 8.88, 8.55 and 8.68 kcal/mol,
respectively. E-ionone rings show a distinguishable shoulder in the conformational
barrier at approximately -110° similar to

p-ionone

stabilize the quasi-s-trans conformation.
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rings. Substituents on the ring seem to

2.3.4. End-groups
The effect of the type of end-group,

13- or E-ring, on the conformational barrier

was investigated by comparing the energy diagram of 13-apo-p-carotene with (6R)-13-

apo-E-carotene in figure 23, (3R)-hydroxy-15-apo-p-carotenal with (3R,6R)-3-hydroxy15-apo-E-carotenal in figure 24; and 3-oxo- 1 5-apo-p-carotenal with (6R)-3-oxo- 1 5-apo-Ecarotenal in figure 25. Epsilon rings, unlike beta rings, contain a stereocenter at carbon 6
which leads to at least two possible steromers. For simplicity, the 6R stereomer of the
epsilon rings was used in every comparison. The structures of the apocarotenoids are

shown in figures 15 and 20.
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Figure 23. Conformational barrier of 13-apo-p-carotene (0) and (6R)-13-apo-E-carotene
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Figure 24. Conformational barrier of (3R)-hydroxy- 1 5-apo-p-carotenal (L) and

(3R,6R)-3-hydroxy-15-apo-E-carotenal (A)
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Figure 25. Conformational barrier of 3-oxo-15-apo-p-carotenal (+) with (6R)-3-oxo-15apo-s-carotenal (X)
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The conformational barriers for the

E-ring are

dramatically different than that

observed for the P-rings. In all of the c-ionone ring systems, only one strong minimum in
the potential curve was observed, occurring at approximately 1200. No symmetry in the
potential curve is seen with respect to either s-cis or s-trans as is observed with

p-ionone

rings.
The overall conformational barrier for E-ionone rings ranged in value from 8.55 to
8.88 kcal/mol, significantly larger than that observed for 1-ionone rings which ranged in
value from 3.06 to 3.40 kcal/mol. The energy difference between the most stable and the
second most stable conformation was significantly larger for epsilon rings (0.92-3.06
kcal/mol) than for beta rings (0.03-0.27 kcal/mol). A striking similarity between the
conformational barriers for the two types of rings is the shoulder for the quasi-s-cis
conformation, as described above.

2.3.5.

Stereochemistry
The effect of the different stereoisomers on the conformational barrier was

investigated by comparing the energy diagram of (3R)-hydroxy-15-apo-3-carotenal with
(3S)-hydroxy-15-apo-p-carotenal in figure 27; and (3R,6R)-3-hydroxy-15-apo-ccarotenal, (3S,6R)-3-hydroxy-15-apo-E-carotenal, (3S,6S)-3-hydroxy-15-apo-E-carotenal
and (3R,6S)-3-hydroxy-15-apo-e-carotenal in figure 28. Figure 26 shows the two
possible isomers of 3-hydroxy- 1 5-apo-p-carotenal and the four possible isomers of 3hydroxy- 1 5-apo-F-carotenal. The conformational barrier of (3S)-hydroxy- 1 5-apo-pcarotenal was used to model meso-zeaxanthin and (3S,3'S)-zeaxanthin while the
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conformational barrier of the diastereomers of 3-hydroxy- 1 5-apo-E-carotenal was used to
model lutein, 3'-epilutein, 6'-epilutein, 3',6'-epilutein and 3,6'-epilutein, the
diastereomers of lutein found in nature.

3-hydroxy- 1 5-apo-p-carotenal

O

(3R)-hydroxy-15-apo-p-carotenal
O(O)

HO

O

(3S)-hydroxy-15-apo-p-carotenal

(+)
HO

3-hydroxy- 1 5-apo-E-carotenal

(3R,6R)-3-hydroxy-15-apo-E0

carotenal (0)

HO

(3S,6R)-3-hydroxy-l5-apo-Ecarotenal (0)
HO

(3S,6S)-3-hydroxy-15-apo-Ecarotenal (A)

*

HO

(3R,6S)-3-hydroxy-15-apo-E-

,,,,.",

°carotenal

(X )

Hoy°

Figure 26. Possible isomers of 3-hydroxy- I 5-apo-p-carotenal and 3-hydroxy- 1 5-apo-Ecarotenal
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The conformational barrier for (3R)-3-hydroxy-15-apo-r-carotenal (O) differs
from that of (3S)-3-hydroxy-15-apo-p-carotenal (+) in the overall shape, the
conformational energy barrier and in the energy difference between the most stable and
the second most stable conformation. (3S)-3-hydroxy-15-apo-P-carotenal shows a
minimum at -46.3o and a second minimum at 46.80. The energy difference between the
most stable and the second most stable conformation is 0.55 kcal/mol compared to 0.24
kcal/mol for (3R)-3-hydroxy-15-apo-p-carotenal.

The conformational barrier for (3R)-3-

hydroxy-15-apo-p-carotenal is 3.18 kcal/mol while that of (3S)-3-hydroxy-15-apo-Pcarotenal is 3.35 kcal/mol.
The conformational barrier for (3R,6R)-3-hydroxy-15-apo-E-carotenal shows a
minimum at 113.3° and a second minimum at -23.3°, only 0.92 kcal/mol in energy

higher. The conformational barrier for (3S,6S)-3-hydroxy-15-apo-E-carotenal (A) is
identical but reversed to that of (3R,6R)-3-hydroxy-15-apo-E-carotenal (O), thus the
stereocenter at carbon 6 dictates the energy barrier. As expected, the two enantiomers
rotate in opposite directions to achieve the same conformation. The conformational

barrier for (3S,6R)-3-hydroxy-15-apo-E-carotenal (Z) resembles that of (3R,6R)-3hydroxy-15-apo-E-carotenal (O) with the only difference in the position of the second
most stable conformation, -27.5°. As seen for the cis-enantiomers, in which the polyene
chain and the substituent on carbon 3, the trans-enantiomers show an inversion of the
conformational barrier. The energy difference between the most and second most stable
structure is 0.92 kcal/mol. The conformational barrier for the cis-enantiomers is 8.55
kcal/mol while that of the trans-enantiomers is 9.05 kcal/mol.
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2.4.1. Discussion
The observed position of the most stable and second most stable conformer along
with the energy difference among them and the overall conformational barrier is
summarized in table 2.

Table 2. Summary of conformational barrier parameters

Structure

Most Stable Second Most
Stable
Geometry
Geometry

Energy
Difference
(kcal/mol)

Conformational
Barrier
(kcal/mol)

11-apo-(3-carotene
13-apo-p-carotene
15-apo-p-carotene
15-apo-p-carotenal

49.20
48.2*
47.8
49.60

-51.4
-49.20
-47.9
-45.9

0.35
0.33
0.34
0.27

3.25
3.18
3.16
3.06

(3R)-hydroxy-15-apo-3carotenal

46.7*

-47.40

0.24

3.18

(3S)-hydroxy-15-apo-p-

-46.3

46.8

0.55

3.35

47.30
122.50

-49.80
-39.60

0.03
3.05

3.40
8.88

113.30

-23.3*

0.92

8.55

113.30

-27.50

0.92

9.05

-113.30

27.50

0.92

9.05

-113.3

23.30

0.92

8.55

120.30

-45.6°

3.06

8.68

carotenal

3-oxo- 15-apo-p-carotenal
(6R)-13-apo-E-carotene
(3R,6R)-3-hydroxy- 1 5-apoE-carotenal

(3S,6R)-3-hydroxy-15-apoE-carotenal

(3R,6S)-3-hydroxy-15-apoE-carotenal

(3S,6S)-3-hydroxy-15-apoE-carotenal

(6R)-3-oxo-15-apo-Ecarotenal

The conformational energy curve is greatly affected by the type of ring present in
the carotenoid. A large barrier is observed for the interconversion of conformers in the
epsilon rings (8.55-9.05 kcal/mol) when compared to beta rings (3.06-3.40 kcal/mol. The
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energy difference between the most stable and second most stable conformer in beta rings
range from 0.03 kcal/mol for 3-oxo-15-apo-p-carotenal to 0.35 kcal/mol for 11-apo-pcarotene. The position of the most stable and second most stable conformers in beta rings
is in agreement with previously reported data. [56] The conformational curve for all beta
groups investigated possessed symmetry with respect to the s-cis conformation. The
torsion angle for the two most stable geometries is approximately ±46.7-49.2°, which
indicates a preference for the s-cis conformer. The substituent present at C3 does not
alter the position of the minima, but it does affect the energy between them. When a
hydroxyl group is present, a slight decrease in the energy difference is observed. The
effect of the substituent is even more pronounced for the presence of an oxo group at C3.
Also, we must not forget that the change in hybridization at C3 may also affect the
energy difference between the most stable and second most stable conformer.
In the case of the epsilon-rings, only one strong minimum is observed at 113.3-

122.50, as previously reported. [58] A pair of enantiomers such as (3R,6R)-3-hydroxy15-apo-E-carotenal and (3R,6R)-3-hydroxy-15-apo-E-carotenal have identical but
reversed conformational barrier. Identical symmetry is observed in barrier for the pair of

enantiomers, (3R,6S)-3-hydroxy-15-apo-E-carotenal and (3S,6R)-3-hydroxy-15-apo-Ecarotenal. Among the four stereoisomers studied, the energy barrier for the trans isomers
in which the 3-hydroxy and the polyene chain are trans to one another is slightly higher
than that for the cis isomers. The stereocenter at C6 determines the direction of the

conformational barrier. (3R,6R)-3-hydroxy-15-apo-E-carotenal and (3S,6R)-3-hydroxy15-apo-E-carotenal have similar energy barriers.
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The consequence of a high-energy barrier for rotation of the E-ring system is that
retinoids containing this structure will be more rigid than those possessing a P-ring.
Accommodation of the

E-ring into non-ideal

protein pockets would require that either the

ring adopt a non-preferred conformational geometry or that the protein tense itself to an
accommodating tertiary conformation. This accounts for the known specificity of

photosynthetic proteins for zeaxanthin or lutein in specific sites.
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CHAPTER III:

STUDY OF THE BIOAVAILABILITY OF XANTHOPHYLL ESTERS IN
HUMANS

3.1.

Overview
The human diet supplies the necessary carotenoids to maintain a constant supply

to the major tissues of the body in which carotenoids are accumulated such as the human
macula and serum. The bioavailability of carotenoids is dependant on several factors
including the carotenoid profile of the diet, the physical and chemical properties of the
carotenoids, the release from the food matrix, transfer to lipid micelles, uptake by
intestinal mucosal cells by passive diffusion, and transport to the lymph system. [59]
Each step in the absorption of carotenoids influences the bioavailability and thus
hindering the assessment. Numerous studies have measured the physiological
concentrations of several carotenoids in serum in an attempt to determine the
bioavailability of such carotenoids after supplementation. [60, 61] In the LUNA study,
supplementation with 12 mg of lutein and 1 mg of zeaxanthin provided as esters along
with other co-antioxidants resulted in an approximately four-fold increase in serum lutein
concentration. In the LUXEA study, supplementation with 10 mg of free lutein resulted
in an approximately seven-fold increase in the serum lutein concentration. The
variability in the results may be attributed to the supplement formulation.
In the current study, the bioavailability of a lutein ester supplement was
determined by HPLC. The main objectives of this study were four-fold. First, determine
the effect of low dose xanthophyll ester supplementation on the carotenoid serum
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response of 30 healthy individual as compared to placebo. Second, determine the
concentration of the major serum carotenoids, specifically lutein, zeaxanthin, 13-carotene,

c-carotene, a -cryptoxanthin and P-cryptoxanthin, at baseline and post-supplementation
and the effect of lutein supplementation on their concentration. Third, determine the
concentration of four lutein metabolites at baseline and post-supplementation. Lastly,
determine the relationship between the concentration of xanthophylls in serum and

cholesterol, triglycerides, HDL, LDL, VLDL and C-reactive protein before and postsupplementation.

3.2.

Research Methodology

3.2.1.

Internal Standard Preparation

Synthesis of Lutein
Lutein used for the preparation of the internal standard, monopentyl lutein ether,
was extracted from esterified carotenoids harvested from Marigold flowers (Targetes

Erecta). The esterified carotenoids were dissolved in methanol and saponified for 12
hours by the addition of aqueous potassium hydroxide to produce a 4% solution in 10%
deionized water. The reaction was performed in the dark under constant magnetic
stirring. The reacted solution was filtered using a P8 qualitative filter (Fisher Scientific,
24.0 cm in diameter) to remove the esterified carotenoids still undissolved; and
neutralized by the dropwise addition of concentrated glacial acetic acid (Fisher Scientific,

64-19-7).
The neutral solution was then evaporated using a rotary evaporator to a fourth of
its volume and the carotenoid mixture extracted three times with equal volumes of
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methylene chloride (Fisher Scientific, 75-09-2) and deionized water. The organic layer
was collected, dried using magnesium sulfate anhydrous (Fisher Scientific, 7487-88-9)
and the solvent removed using a rotary evaporator.

Column Chromatography for the separation of lutein
The column packing was prepared by mixing CaCO 3 (calcium carbonate, Fisher

Scientific 471-34-1), MgO (magnesium oxide, light; Sigma-Aldrich 1309-48-4) and
Ca(OH) 2 (calcium hydroxide, Fisher Scientific 1305-62-0) in a 29.5, 6 and 5 ratio. The
mixture was agitated vigorously and passed through an 80-mesh sifter. The column was
prepared in a 600 mm glass column with a 40-60 micron pore size glass fritted disc and

PTFE Stopcock plug (Kontes, 420540). Hexane (Fisher Scientific, 110-54-3) was
continuously added to prevent the packing material from drying.
The column was packed by adding a thin layer of washed sea sand (Fischer

Scientific, 14808-60-7), 1 cm in height, and approximately 600 g of the pre-mixed
packing material. The packing material was allowed to settle for several hours assisted
by the continuous addition of hexane and pressurized air. Once the material became
homogeneous without visible cracks, the level of the hexane was adjusted to 1 cm above
the packing material. The dried carotenoid mixture was slowly added to the top of the
column without disturbing the packing material, followed by a thin layer of sand,
approximately 2 cm in height. The carotenoid mixture was prepared by dissolving
approximately 50 mg of carotenoids in 10 mL of methylene chloride, adding
approximately 2 g of packing material and removing the solvent using rotary evaporation.
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The residue was scratched from the sides of the round-bottom flask and added directly to
the column.
Hexane was used to elute the first yellow band containing the esterified
carotenoids. Separately, a mixture of hexane, chloroform (Fischer Scientific, 67-66-3)
and acetone (Fischer Scientific, 67-64-1) in a 3:2.4:0.5 ratio by volume was prepared and
added to the column as to slowly adjust the solvent composition depending on the
separation.

Monopentyl lutein ether standard preparation
Monopentyl lutein ether (MPL) was used as an internal standard for HPLC

analysis (System II). 5 mg of lutein was dissolved in 20 mL of 1-pentanol (Acros, 71-410) containing 1% by volume of concentrated hydrochloric acid (Fischer Scientific, 764701-0) and stirred magnetically for 4 hours in the dark. The solution was extracted 3 times
with methylene chloride and deionized water, and purified by reverse phase HPLC
(System I). MPL was then dissolved in ethanol to a fixed volume, and its concentration
determined using a ultraviolet-visible Spectrophotomer.

3.2.2.

Serum sample preparation

Subjects
30 healthy, non-smoker volunteers were recruited from the F.I.U. community
using an institutional review board approved recruitment posting (Appendix I) and
randomly assigned to one of the three study groups: placebo, low dose or high dose. The
study included both males and females as well as members of minority populations. The
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study excluded: individuals who are smokers, pregnant or planning pregnancy, diabetics,
hypertensive, those with gastrointestinal disorders and individuals taking statin drugs or
other prescriptions chronically.
Subjects were interviewed and instructed on the research protocol, benefits and
possible risks of the study. An institutional review board approved consent form
(Appendix II) was required from each individual. No personal data with the exception of
age and sex was acquired and retained for correlation to the experimental results.

Study Supplements
Study supplements were provided in a hard shell gelatine capsule containing
esterified lutein extracted from marigold flowers (Targetes erecta) or placebo. The
esterified lutein contained approximately 7 % esterified zeaxanthin. The capsules were
acquired from Biolut. The analysis of the capsule resulted in xanthophylls doses of 3 mg
of lutein equivalent per capsule for the low dose supplement and 6 mg of lutein
equivalent per capsule for the high dose supplement.

Subjects were instructed to take the

daily supplement with a meal at a regular time.

Blood Collection
10 mL of venous blood were collected in Vacutainer separator tubes at the
University Health Center before supplementation and every 2 weeks during the 8-week
intervention (total of 5 blood serum collections). The first and last blood collections were
done after overnight fast for analysis of lipid parameters. Blood was allowed to clot for
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30 minutes and centrifuged for 10 min at 3000 rpm. The serum samples were stored at 80°C in 2 mL polypropylene tubes until extraction and analysis on HPLC (System II).

Lipid Panel
Fasting blood samples were collected before supplementation (day 0) and postsupplementation (day 60) and sent for analysis at a local clinical laboratory. The lipid
parameters measured were: cholesterol, high-density lipoprotein (HLD), low-density

lipoprotein (LDL), very low-density lipoprotein (VLDL), triglycerides and C-reactive
protein.

Serum sample extraction
Serum samples were prepared according to previously established techniques.
[62] The serum sample was removed from the freezer and thawed for 20 minutes. After
vortexing the sample for 30 seconds, 200

tL of serum and 20

tL of monopentyl lutein

ether dissolved in ethanol (AAPER, Absolute 200 proof) were combined in a 100 x 13

mm borosilicate glass tube with a Teflon lined screw cap. 2 mL of 1:1 methanol
(Fischer Scientific, 67-56-1):deionized water mixture (v:v) was added to precipitate the
serum proteins and the carotenoids extracted 3 times with 2 mL of hexane. After the
addition of hexane, the mixture was vortexed for 1 minute and centrifuge for 5 minutes.
The top hexane layer containing the dissolved carotenoids was drawn with a glass Pasteur
pipette into a 2 mL polypropylene vial. The aliquots were combined and dried under a
stream of nitrogen gas. The sample was re-dissolved in 40 tL of ethanol and transferred
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to a 250 pL polypropylene vial (Waters, WAT094172) for injection into HPLC (System
II).

3.2.3.

Chromatographic Separations

System I
MPL was purified using reverse phase HPLC on a system composed of a Thermo
Finnigan Spectra System UV 1000 detector coupled to an LDC/Milton Roy Analytical
Constametric 4000 multiple solvent delivery system equipped with a Phenomenex
Ultracarb 10 p.m ODS column (250 x 21.20 mm) and an injection loop volume of 10 mL.
The solvent composition was 85% acetonitrile (Fisher Scientific, 75-05-8), 15% methanol

(Fisher Scientific, 67-56-1) and 0.1% triethylamine (Fisher Scientific, 121-44-8) which
were mixed and degassed prior to introduction into the chromatographic system at a flow
rate of 5 mL/min. The ultraviolet detector was set up at 450 nm.

System II
The serum samples were analyzed using a Waters 2690 Alliance Separation

module equipped with a Waters model 996 Photodiode Array Detector and a Waters 486
Tunable Absorbance Detector set at 450 nm. Carotenoid separations were carried out on
a reversed phase Phenomenex Ultracarb 3 tm ODS (150 x 4.6 mm) with a flow rate of 1
mL/min. The solvent composition used was 85% acetonitrile, 15% methanol, and 0.1%
triethylamine by volume. Samples were run at ambient temperature, generally at 20°C.
25

L of sample was injected into the system and ran for 60.0 minutes.
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System III
Carotenoid esters were analyzed using the chromatographic equipment described
for system II with a YMC 3

m C30 Carotenoid Column (2.0 x 250 mm). A gradient

between solvent A (81% methanol, 4% deionized water and 15% methyl tert-butyl ether,

Fisher Scientific, 1634-04-4) and solvent B (6% methanol, 4% deionized water and 90%
methyl-tert-butyl ether) was used for elution, figure 29, delivered at a flow rate of 0.3
mL/min. The column temperature was adjusted to 35°C. 25 pL of sample dissolved in
ethanol was injected into the system and ran for 70.0 minutes.
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Figure 29. HPLC gradient for the separation of carotenoid ester by System III (solvent
A:81% methanol, 4% deionized water and 15% methyl tert-butyl ether, and solvent B:6%
methanol, 4% deionized water and 90% methyl-tert-butyl ether

3.2.4.

Ultraviolet-visible Spectrophotometer
The concentration of MPL was measured using a Shimadzu double beam UV-

Visible Scanning Spectrophotometer (UV-2101 PC). Mono-pentyl lutein ether (Internal
Standard) was dissolved in ethanol and scanned from 650 to 300 nm. The ultraviolet-
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visible spectrum was measured in a UV self-masking micro cell with PTFE stopper (NSG
precision cells, 30MUV10). Beer's law was used to determine the concentration. The
molar absorptivity of MPL (E) is 1.45 x 10$ M-'.cm~' at 450 nm.

3.2.5.

Statistical Analysis
The data including the serum carotenoid concentrations and lipid parameters was

analyzed using the Statistical Package for the Social Sciences (SPSS). Descriptive
statistics including means and standard deviations were used to analyze the variation in
serum carotenoids and lipid parameters. Two-way analysis of variance and independent
t-test was used to compare differences in carotenoid serum concentration between the
placebo and the supplementation groups and to compare the lipid parameters among the
groups. Results were considered statistically significant at p<0.05. Spearman's
correlations were performed to establish the relationship between serum carotenoids and

lipid parameters.

3.3.

Results

Baseline characteristics
Thirty subjects from the F.I.U. community participated in the study. The baseline
characteristics of the three groups in the study along with baseline values of serum
carotenoids are shown in table 2. The age range of the participants was from 18 to 62
years with a mean age of 24.9 ± 9.7 years. The majority of the subjects, 90% or 27
subjects, were between the ages of 18 and 29 years. No statistical differences, as
determined by one-way ANOVA, were observed in terms of age and the female-to-male
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ratio. 10 males and 20 females participated in the study, equally distributed among the
groups, table 3. The placebo and low dose group each included 70% females and the

high dose included 60% females.

Table 3. Baseline characteristics for supplemented subjects (mean

Age (years)
Female:male

±

standard deviation)

Placebo (n=10)
22.3 ± 4.64
7:3

Low dose (n=10)
26.4 ± 12.9
7:3

High dose (n=10)
26.0 . 10.3

149.5 ± 22.6
62.4 ± 15.3
52.3 ± 5.3
84.5 ± 22.4
12.7 ±3.1
0.09 ± 0.07

178.0 ± 33.6*
85.1 ± 46.4
57.3 ± 11.2
103.6 ± 19.4
17.1 ±9.4
0.20 ± 0.30

191.6 ± 33.9*
96.8 ± 48.9
50.6 ± 12.6
121.8 ± 24.8
19.2 ±9.8
0.14 ± 0.11

15.74 ± 6.69
5.04 ± 1.77
2.98 ± 1.68
10.33 ± 8.98
2.96 ± 2.49
8.63 ± 7.63

14.77 ± 3.77
6.49 ± 2.56
3.34 ± 2.00
13.20 ± 9.88

16.89 ± 8.85
6.55 ± 4.07
3.06 ± 2.12
13.85 ± 13.39
5.19 ± 6.23
13.04 ± 13.60

6:4

Lipid parameters

Cholesterol (mg/dL)
Triglycerides (mg/dL)
HDL Cholesterol (mg/dL)
LDL (mg/dL)
VLDL (mg/dL)
C-reactive protein
Major Serum carotenoids

Lutein (nmol/dL)
Zeaxanthin (nmol/dL)
a-Cryptoxanthin (nmol/dL)
P-Cryptoxanthin (nmol/dL)
c-Carotene (nmol/dL)
f3-Carotene (nmol/dL)

3.24
13.59

±

2.78
14.52

* t-test for equality of means indicate significant difference when compared to baseline
concentration (p<0.05)

The cholesterol levels for the participants ranged from 122 to 262 mg/dL with a
mean serum cholesterol level of 173.0

± 34.4 mg/dL. The baseline cholesterol levels of

the placebo group significantly differed from both the low and the high dose
supplementation group at the p<0.05 level, as determined by one-way ANOVA. The
mean cholesterol level for the placebo group was 149.5
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±

22.6 mg/dL, for the low dose

group 178.0 - 33.6 mg/dL and for the high dose 191.6 ± 33.9 mg/dL. The statistical
differences in the baseline cholesterol levels within the groups, prevented a comparison
with post-supplementation cholesterol levels.
Pearson correlations between the baseline serum lutein concentration and the lipid
parameters revealed a positive linear correlation at p<0.05 between the lutein
concentration and the serum concentrations of cholesterol, figure 30, HDL, figure 31, and
LDL, figure 32, levels for the males but not for the females or when all subjects where
combined. The individual Pearson's product momentum correlation coefficients, r, are
indicated next to each linear trend line and denoted with an asterisk to indicate
significance at p<0.05. Among the females, a greater variability was observed in the
serum parameters and in the serum carotenoid concentration.
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The Pearson's product momentum correlation coefficients and linear trend line
indicates that the male subjects with higher cholesterol, HDL and LDL exhibit higher
serum lutein concentrations at baseline. No correlation was observed with other serum
carotenoids.
The mean serum triglycerides in the study was 81.4 ± 41.2 mg/dL, the mean HDL
cholesterol was 53.4

± 10.2 mg/dL, the mean LDL level was 103.3 ± 26.5 mg/dL and the

mean VLDL level was 16.3

± 8.2 mg/dL. No significant differences were observed for

the baseline levels of triglycerides, HDL cholesterol, LDL and VLDL within the groups
at the p<0.05.
The serum concentration of lutein ranged from 7.41 to 34.34 nmol/dL, with a
mean of 15.79 ± 6.43 nmol/dL. The mean serum concentration of zeaxanthin, a-

cryptoxanthin and P-cryptoxanthin was 6.03 ± 2.80, 3.13 ± 1.88 and 12.46 ± 10.65
nmol/dL respectively.

As in the case of lutein, the responses varied widely within each

group. The mean serum concentration of

c-carotene,

P-carotene and cis-P-carotene was

3.77 ± 4.11, 11.75 + 11.56 and 2.40 ± 1.12 nmol/dL, respectively. No significant
differences were observed between the carotenoid serum concentrations among the three

groups.

Analysis of xanthophyll esters supplement
The analysis of the xanthophyll esters supplement was carried out by System III.
The HPLC chromatogram of the supplement, figure 33, indicate the presence of multiple
fatty acid ester components known to be naturally produced by marigold flowers, the
source of the supplements used. [28]
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Figure 33. HPLC chromatogram of xanthophyll esters supplement

The UV-visible spectra of the individual components, ranging in retention time
from 46.9 to 50.4 min, indicate the presence of five different lutein diesters. The
wavelength of maximum absorbance for all components ranged from 446.8 and 447.2
nm, consistent with that observed for lutein. Esterification does not alter the
chromophore present in the carotenoid, therefore

Xmax

for the lutein diesters equal that of

lutein. In between the main peaks, small overlapping peaks were observed and identified
as the corresponding zeaxanthin diesters which are known to occur naturally in marigold
flowers (Targetes erecta) in approximately 7%. [28] The main source of the xanthophyll
diester supplements was marigold flowers.
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Spectroscopic characterization of serum components
The HPLC chromatogram recorded by System II of a typical serum sample at
baseline is shown in figure 34. The identity, retention time and retention factor for each
component is described in table 4.
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Figure 34. HPLC chromatogram of a typical serum response at baseline (Subject 5, high
dose group). 1: lutein metabolite, 2: lutein metabolite, 3: lutein metabolite, 4: lutein
metabolite, 5: lutein, 6: zeaxanthin, 7: a-cryptoxanthin, 8: P-cryptoxanthin, 9: MPL
(internal standard), 10: lycopene stereoisomers, 11: u-carotene, 12: 1-carotene, 13: cis-p(carotene

The concentration of each component was determined by comparing the area
under each peak with the area of the internal standard monopentyl lutein ether (MPL),
peak 9. MPL is composed of two overlapping peaks corresponding to the diastereomers
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of MPL, monopentyl (3R,3'R,6'R)-lutein ether and monopentyl (3R,3'S,6'R)-lutein ether
produced during the synthesis reaction. The acid-catalyzed ether formation of MPL
produces minor oxidation and dehydration products which were removed by HPLC
(System I). The two broad peaks eluting between minutes 25.5 and 28 and labeled peak
10 in the chromatogram comprise the unresolved lycopene stereoisomers present in
serum. The all-trans-lycopene and 9-, 13- and 15-cis-lycopene have been identified in

serum. [49, 63]

Table 4. Retention time (Rt) and retention factor (k') of carotenoids in human serum
Peak no.

Compound

1
2
3

Lutein metabolite 1
Lutein metabolite 2
Lutein metabolite 3

4
5
6
7
8
9

Lutein metabolite 4
Lutein
Zeaxanthin
a-Cryptoxanthin
p-Cryptoxanthin
Mono-pentyl lutein ether (MPL)

10

Lycopene isomers

11
12
13

c-Carotene
P-Carotene
cis-p-Carotene

Retention time

Retention factor

(mm)

(k')

4.61

1.42

5.21
5.61

1.74
1.95

5.98
6.43
6.95
15.98
17.64
19.88, 20.38
25.5 - 28.0
43.29
47.77
50.21

2.14
2.38
2.65
7.39
8.26
9.44, 9.70
-

21.74
24.09
25.37

The retention factor of the serum carotenoids ranged in value from 1.42 to 25.37.
Retention factors measure the migration rate of the analyte on the column and are a good
indication that the proper solvent composition was used.
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The identity of each component was confirmed by their UV-visible spectrum

given in figure 35 for peak 1 and 2, figure 36 for peak 3 and 4, figure 37 for peak 5 and 6,
figure 38 for peak 7 and 8 and figure 39 for peak 9 and 12; by their retention times and by
comparison with standard solutions when they were available. The serum carotenoids
described below refer to the all-trans carotenoids unless specified otherwise. The
concentration of the components under peaks 10, 11 and 13 was too low to obtain defined
UV-visible spectrum.
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Figure 35. Ultraviolet-visible spectrum of peak 1 and 2

The UV-visible spectrum of peak 1 shows the maximum absorbance at
441.5 nm (Band II) and a second maximum absorbance at
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kmax=

k=471.6 nm (Band III).

The

%III/II of 73.2% is indicative of two E-ionone rings or a

p3-

and an E-ionone ring in the

structure. The UV/visible spectrum of peak 2 shows the maximum absorbance at
441.5 nm (Band II) and a second maximum absorbance at
%III/II of 84.6% is indicative of two E-ionone rings or a

X=469.8

Xmax=

nm (Band III). The

s- and an E-ionone ring in the

structure. Rajendran et al tentatively identified peak 1 through 4 as cis-isomers of lutein
based on their Q-ratios, the ratio of the cis-peak to the main absorption band in the UV-

visible spectra. [64]
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Figure 36. Ultraviolet-visible spectrum of peak 3 and 4

The UV-visible spectrum of peak 3 shows the maximum absorbance at
445.1 nm (Band II) and a second maximum absorbance at
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X.max=

k=473.4 nm (Band III).

The

%IIIlII of 15.7% is indicative of one c-ionone and one P-ionone ring in the structure.
Peak 3 has been previously determined to be oxo-lutein (3-hydroxy-P, -carotene- 3'one).. The UV/visible spectrum of peak 4 shows the maximum absorbance at

Xmax=

441.5

nm (II) and a second maximum absorbance at X=469.8 nm (III). The %III/II of 65.9% is
indicative of two e-ionone rings or a

p3-

and an E-ionone ring in the structure.
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Figure 37. Ultraviolet-visible spectrum of peak 5 and 6

The UV-visible spectrum of peak 5 shows the maximum absorbance at
447.3 nm (Band I) and a second maximum absorbance at

X=475.6

Xmax

of

nm (Band III). The

%III/I of 56% and the retention time is consistent with that obtained for the lutein
standard. The UV-visible spectrum of peak 6 shows the maximum absorbance at
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Xmax

of

453.5 nm (Band II) and a second maximum absorbance at X=479.3 nm (Band III). The
%III/II of 28% and the retention time is consistent with that obtain for the zeaxanthin
standard. At higher serum lutein concentrations, obtained after 30 days of
supplementation in both the low and high dose group, a peak consistent with cis-lutein
was observed overlapping with the zeaxanthin peak.
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Figure 38. Ultraviolet-visible spectrum of peak 7 and 8

The UV-visible spectrum of peak 7 shows the maximum absorbance at
xmax=446.1

nm (Band II) and a second maximum absorbance at

The %III/II of 67% is consistent with the presence of a

X=474.8 nm

p-ring and

(Band III).

an E-ring and the

retention time is consistent with that expected for a-cryptoxanthin. The UV-visible
spectrum of peak 8 shows the maximum absorbance at
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Xmax=449.8

nm (Band II) and a

second maximum absorbance at

k=477.2 nm (Band III).

The

°%III/II

of 210% is consistent

with that of two P-rings and the retention time is consistent with that expected for

P-

cryptoxanthin.
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Figure 39. Ultraviolet-visible spectrum of peak 9 and 12

The UV-visible spectrum of MPL is identical to that of lutein, figure 37.
Derivatization at C3' does not affect conjugation at the polyene chain, thus it does not
affect the UV-visible spectrum. Peak 9 shows a maximum absorbance at
(Band II), a second maximum absorbance at
Peak 12 shows a maximum absorbance at
maximum absorbance at

k=475.9

kmax=

4

nm (Band III) and a

447

%III/Il

50. 8 nm (Band II) and a second

k=478.2 nm (Band III). The %III/II

60

kmax=

of 61% indicates the

.5 nm

of 61%.

presence of two

P-rings and the retention time is consistent with that obtained for the

p-

carotene standard.

Supplementation response
The HPLC chromatogram of a serum sample in the high dose group after
supplementation is shown in figure 40.
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Figure 40. HPLC chromatogram of a typical serum response in the high dose group after
supplementation (Subject 5)

A marked increase in the serum concentration of lutein was observed after
supplementation in both the low dose and the high dose groups, figure 41. The increase
reached a plateau concentration after day 15, with a mean concentration of 34.28
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-17.96

and 71.41 ± 35.98 nmol/dL for the low dose and high dose group, respectively. The error
bars indicate the variability within the groups. The serum lutein concentration of the low

dose and high dose groups was significantly different from the placebo group (p<0.05) at
every supplemented serum collection (day 15 to day 60). The serum lutein concentration
was significantly different for the low and high dose supplementation group at day 15, 30
and 45. At day 60, the serum lutein concentration of the high dose was higher that the
serum lutein concentration for the low dose group but it did not reach statistical
significance at p<0.05. The decrease in serum concentration for the high dose at day 60
was attributed to decreasing compliance among the subjects as the study progressed.
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Figure 41. Mean (+ SD) serum lutein concentration for each group: placebo in white,

low dose in gray and high dose in black
* Significant difference when compared to baseline concentration (p<0.05), ** p<0.002

*** Significant difference when compared to low dose concentration (p<0.05)
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The increase in concentration of lutein was proportional to the dose
supplemented, figure 42. In the low dose group an approximately 2-fold increase was
observed while in the high dose group an approximately 4-fold increase was observed.
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Figure 42. Increase in lutein serum concentration with dose

Pearson's correlations after adjusting for the different supplementation doses
revealed a correlation between the final serum lutein concentration and the baseline

concentrations of triglycerides, figure 43, HDL, figure 44, VLDL, figure 45 and Creactive protein, figure 46 for the males at p<0.05. No correlation was observed for the
females or when all subjects were combined. Among the females, a greater variability
was observed in the serum parameters and in the serum carotenoid concentration. No
correlation was observed with other serum carotenoids.
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Figure 43. Correlation between post-supplementation serum lutein concentration and
baseline triglycerides concentration for females r-0.106 (O), males r=0.799* (0) and
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Figure 44. Correlation between post-supplementation serum lutein concentration and
baseline HDL concentration for females r-0.319 (O), males r-0.838* (L) and combined
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Figure 45. Correlation between post-supplementation serum lutein concentration and
baseline VLDL concentration for females r-0.112 (O), males r-0.799* (0) and
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The Pearson's product momentum correlation coefficients are given next to the

linear trend lines and they indicate that the baseline serum concentration of triglycerides,
HDL, VLDL and C-reactive protein are correlated with the supplementation response.
Male subjects with higher triglycerides, VLDL and C-reactive protein were lower

responders while subjects with lower HDL were lower responders.
The serum concentration of zeaxanthin also increased proportional to dose, figure
47. The baseline serum concentration of all supplementation groups did not differ
significantly. A decrease in zeaxanthin serum concentration was observed at day 45 for
all groups, this was attributed to overlap with lutein cis peaks at increasing lutein
concentrations. Asterisks indicate significant difference at p=0.05 and/or p=0.01.
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Figure 47. Mean (± SD) serum zeaxanthin concentration for each group: placebo in
white, low dose in gray and high dose in black
* Significant difference when compared to baseline concentration (p<0.05),
** Significant difference when compared to low dose concentration (p<0.05)
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The serum concentration of zeaxanthin increased from an average baseline of 6.03

* 2.80 nmol/dL to 8.03 ± 2.70 and 12.23 ± 5.85 nmol/dL for the low and high
supplementation groups, respectively. The serum concentration of four lutein metabolites
also increased proportional to dose labeled lutein metabolite 1 through 4, figures 48 to 51.
The serum concentration of the lutein metabolites for all groups did not differ
significantly at baseline.
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Figure 48. Lutein metabolite 1 serum concentration: placebo in white, low dose in gray
and high dose in black
* Significant difference when compared to baseline concentration (p<0.05), ** p<0.001,
*** Significant difference when compared to low dose concentration (p<0.05)

The serum concentration of lutein metabolite 1 increased from an average
baseline of 1.24 ± 0.48 nmol/dL to 1.64 ± 0.67 and 2.74

1.24 nmol/dL for the low and

high supplementation groups, respectively. The increase in the concentration of lutein
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metabolite 1 occurred at a lower rate for the low dose supplementation group than for the
high dose supplementation group and it was only dose dependant at day 60.

c

10.0
9.0
L

**

**

8.0

7.0
3

6.0

N

5.0
4.0

3.0
2.0

1.0
a

0.0
Day

0

Day 15

Day 30

Day 45

Day 60

Supplementation Day
Figure 49. Lutein metabolite 2 serum concentration: placebo in white, low dose in gray

and high dose in black
* Significance difference when compared to baseline concentration (p<0.05), ** p<0.001,
*** Significant difference when compared to low dose concentration (p<0.05), **** p
<0.001

The serum concentration of lutein metabolite 2 increased from an average
baseline of 1.72

±

0.74 nmol/dL to 2.56 ± 1.05 and 5.41 ± 2.51 nmol/dL for the low and

high supplementation groups, respectively. The serum concentration of lutein metabolite
3 increased from an average baseline of 2.87

±

1.04.74 nmol/dL to 3.43 ± 1.27 and 5.36

2.25 nmol/dL and of lutein metabolite 4 from an average baseline of 1.39

±

0.67 nmol/dL

to 1.84 ± 1.11 and 2.10 ± 1.15 nmol/dL for the low and high supplementation groups,
respectively.
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Figure 50. Lutein metabolite 3 serum concentration: placebo in white, low dose in gray
and high dose in black
* Significant difference when compared to baseline concentration (p<0.05), ** p<0.001,
*** Significant difference when compared to low dose concentration (p<0.05)
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The serum concentration of other serum carotenoids, a-cryptoxanthin, (cryptoxanthin, a-carotene,

P-carotene

and cis-o-carotene did not change significantly

after supplementation, table 5. The serum concentration of each serum component at
baseline was averaged to obtain a more significant representation of the population.

Table 5. Mean (± SD) major serum carotenoids at baseline and post-supplementation for
each group
Baseline

Post-supplementation (nmol/dL)

(nmol/dL)

Placebo

Low Dose

metabolite 1

1.24 ±0.48

1.14 ±0.36

1.64 ±0.67*

High Dose
2.74± 1.24**

metabolite 2

1.72±0.74

1.40 ±0.55

2.56± 1.05*

5.41 ±2.51**

metabolite 3

2.87 ± 1.04

2.34 ± 0.96

3.43 ± 1.27*

5.36 ± 2.25*

metabolite 4

1.39 ± 0.67

1.13 ±0.53

1.84 ± 1.11*

2.10 ±1.15*

lutein

15.79

15.11 ± 7.35

34.28 ± 17.96*

71.41 ± 35.98**

zeaxanthin

6.03 ± 2.80

5.03

1.77

8.03 ± 2.70*

12.23 ± 5.85*

a-cryptoxanthin

3.13

2.14

1.22

3.08

1.65

2.68

1.45

12.46 ± 10.65

9.22

7.14

12.77

9.23

12.68

14.35

c-carotene

3.77 ± 4.11

5.66

9.37

3.98

2.73

P-carotene

11.75 ±11.56

10.97

7.75

P-cryptoxanthin

cis-p-carotene

6.43
1.88

2.40 ± 1.12

1.73 ± 1.20

16.06± 11.26
1.64

0.26

4.45 ± 6.20
8.10± 5.25
-

* Significant difference when compared to baseline concentration (p<0.05), ** p<0.001

3.4.

Discussion
The baseline concentration of the serum carotenoids obtained was in agreement

with previously reported values. [60-62, 64-66] In males, the baseline levels of lutein
were correlated with the baseline levels of cholesterol, HDL and LDL. These trends did
not reach statistical significance in the females or the group as whole and this is probably
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a consequence of the relatively small study size and the sensitivity of a small study to
variability in the group. Further investigation of the lutein cholesterol relationship is
needed but we would note that the general carriers of carotenoids in serum are the
lipoproteins and it has been reported that the proportion of lutein carried by HDL is
greater than LDL. The cause of a slightly higher correlation with total cholesterol is
likely the result of the subtleties of how these values are derived from the analytical

methodology.
Lutein supplementation in our study groups demonstrates a clear relationship
between serum response and dosage of the lutein supplement. Males and females were
present in all three dosage groups of this study and we have observed significant and
comparable responses to supplementation for both males and females.

Both the 3 and 6

mg (equivalent of free lutein) doses produced significant serum responses at p< 0.005 by
day 15 of supplementation. The 3 mg dose resulted in a >2 fold increase upon
supplementation and 6 mg dose produced a >4 fold increase in serum lutein level. The

serum response remains elevated for subjects at both doses throughout the
supplementation trial although there is a small decrease in serum level clearly visible and
we attribute this to decreasing compliance of study subjects as the study progressed.
Zeaxanthin is a minor component of the supplement (~7%) and an increase in the
serum levels of the study participants was observed for both doses. The 3 mg dose
(lutein equivalent) would provide approximately 0.21 mg of zeaxanthin and results in a
serum response of 1.3 fold over baseline. The 6 mg dose (lutein equivalent) would
provide approximately 0.42 mg of zeaxanthin and results in a 1.9 fold increase in serum
zeaxanthin over baseline. These increases are statistically significant on day 15 of
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supplementation with p values <0.05. There is some variability in the serum level of
zeaxanthin during the supplementation period with the results at day 30 and 45 being
below statistical significance for the 3 mg (free lutein equivalent) dose and also on day 45
for the 6 mg (free lutein equivalent) although there is a clear increase in the average
serum zeaxanthin concentration on all dates.
The serum response of lutein is 0.72 nmol/dL mg equivalent free lutein. The
response for zeaxanthin ranged between 4.8 and 6.5 nmol/dL mg equivalent of free
zeaxanthin when determined on the day 15 data. Lower response rates would be
calculated from data obtained on subsequent measurements. It would appear that the
zeaxanthin serum response to supplementation is significantly higher than that of lutein
but the variability in these data resulting from the relatively low dose of this carotenoid
makes this measurement questionable.
In addition we observed that in males but not females the serum increase in lutein
is correlated with the baseline level of lipids. For triglycerides a negative correlation is
observed. We do not have an adequate explanation for this observation and there is no
obvious reason why such a relationship should exist for males but not females. The
serum response of lutein in men shows a positive correlation to baseline HDL and is a
trend one would expect if HDL is the dominant carrier of lutein in the serum. A
significant negative correlation is also observed between the serum response of lutein and
serum VLDL for males but not females. A final observation that was found in males but
not females in this study was a negative correlation between baseline serum C-reactive
protein and the serum lutein supplementation response. A speculative hypothesis for this
observation would be that C-reactive protein is a marker for oxidative stress and
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inflammation and that higher stress levels in subjects would predict lower lutein
responses because absorbed lutein is degraded to a greater extent.
In addition to the lutein and zeaxanthin concentration increases there are
measurable levels of the xanthophyll metabolites that increase significantly during the
supplementation period. Other carotenoids, including lycopene, a- and

p3-cryptoxanthin,

a- and 3-carotene do not change significantly during the supplementation period. We
conclude that any competition for the absorption is insignificant at the level of
supplementation we are conducting in this study and therefore these supplements will not
have a negative influence on the level of other nutritionally significant carotenoids.
This study demonstrates that lutein esters are highly bioavailable in humans when
provided in capsules containing 3 or 6 mg/day equivalent of free lutein. The natural
zeaxanthin component of this ester formulation is also highly bioavailable and produces

statistically significant serum increases although with much greater variability in the
measured values.
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CHAPTER IV:
CONCLUSIONS

The purpose of this study was to assess the bioavailability of a low dose
xanthophyll ester supplement in serum and to help understand the importance of the
conformational barrier for rotation in biological important carotenoids. Nearly all
carotenoids present in serum, with the exemption of lycopene, contain either a

P-

or an

E-

ionone ring, thus understanding the significance of these rings on the structure and
properties will shed light onto why certain carotenoids are absorbed from the diet while
others are not. The major serum carotenoids with 1-ionone rings include
zeaxanthin and

P-cryptoxanthin and

with both

p- and E-ionone

p-carotene,

rings include lutein, a-

cryptoxanthin and c-carotene.
The study demonstrates that the conformational energy curve is greatly affected
by the type of ring present in the carotenoid. A large barrier is observed for the
interconversion of conformers in the epsilon rings in which the conformational barrier

ranges in value from 8.55 kcal/mol for (3S,6S)-3-hydroxy-15-apo-E-carotenal

and

(3R,6R)-3-hydroxy-15-apo-E-carotenal to 9.05 kcal/mol for (3S,6R)-3-hydroxy-15-apo-Ecarotenal and (3R,6S)-3-hydroxy-15-apo-E-carotenal

when compared to beta rings for

which the conformational barrier ranges in value from 3.06 kcal/mol for 15-apo-Pcarotenal to 3.40 kcal/mol for 3-oxo-15-apo-p-carotenal, table 6. These results indicate
that the

E-ionone

ring must overcome a larger potential energy barrierto rotation in order

to adopt certain conformations than is required for a
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p-ionone

ring. The energy

difference between the most stable and second most stable conformation was larger for
the E-rings in which it ranged from 0.92 to 3.06 kcal/mol than for p-rings in which the
energy difference ranged from 0.24 to 0.35 kcal/mol.

Table 6. Summary of selected conformational barrier parameters

Structure

15-apo-p-carotenal
(3R)-hydroxy-15-apo-p-

Mos
StbleSecond Most

Most
GGeometry

Stable

0.24

3.18

-46.3

46.8

0.55

3.35

47.30
122.50

-49.80
-39.60

0.03
3.05

3.40
8.88

113.30

-23.30

0.92

8.55

113.30

-27.50

0.92

9.05

-113.3°

27.50

0.92

9.05

-113.3°

23.30

0.92

8.55

120.30

-45.6"

3.06

8.68

apo-E-carotenal

(3S,6S)-3-hydroxy-15-

3.06

-47.4

apo-F-carotenal

(3R,6S)-3-hydroxy-15-

0.27

46.70

apo-E-carotenal

(3S,6R)-3-hydroxy-15-

onformational
Barrier (kcal/mol)

49.60

carotenal

3-oxo- 15-apo-p-carotenal
(6R)-13-apo-E-carotene
(3R,6R)-3-hydroxy-15-

(kcal/m)

apo-E-carotenal

(6R)-3-oxo-15-apo-E-

Cnomtoa

Geometry
-45.90

carotenal

(3S)-hydroxy-15-apo-p-

Energy

Difference
mol)

carotenal

Other factors such as the length of the apocarotenal, the chain termination and the
presence of various functional groups at carbon 3 do not significantly affect the
conformational barrier. The presence of a stereocenter at carbon 6 in the E-ionone rings
dictates the rotational direction of the conformational barrier while the presence of a
stereocenter at carbon 3 weakly influences the overall conformational barrier. The
conformation barriers of the enantiomers, (3R,6R)-3-hydroxy- I 5-apo-E-carotenal and
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(3S,6S)-3-hydroxy-15-apo-E-carotenal, are identical but reversed. The conformational
barriers of the diastereomers, (3R,6R)-3-hydroxy-15-apo-E-carotenal and (3R,6S)-3hydroxy- 1 5-apo-E-carotenal, were not identical as would be expected for diastereomers
but differ in the overall conformational barrier. The importance of these structural
differences between carotenoids and the mechanism by which carotenoids exert their
effect on human health remains incompletely understood.
The results from the supplementation study suggest that xanthophyll esters are

highly bioavailable in humans. The post-supplementation concentrations of lutein
increased two- and four-fold in the 3 and 6 mg of lutein equivalent per day, respectively.
The study suggests that the serum increase in lutein is correlated with the baseline level
of lipids for the males but not for the females. A study by Brady et al. found that all
serum carotenoids were significantly related to total cholesterol and non-HDL cholesterol
and that lutein + zeaxanthin was related to HDL cholesterol. [65] In the present study we
observe a direct significant relation between the baseline serum levels of lutein with that

of cholesterol (r=0.875), HDL (r-0.748) and LDL (r-0.188).
Zeaxanthin is a minor component of the supplement (~7%) and an increase in the
serum levels of the study participants was observed for both doses. The 3 mg dose
(lutein equivalent) would provide approximately 0.21 mg of zeaxanthin and results in a
serum response of 1.3 fold over baseline. The 6 mg dose (lutein equivalent) would
provide approximately 0.42 mg of zeaxanthin and results in a 1.9 fold increase in serum
zeaxanthin over baseline.
In addition to the lutein and zeaxanthin concentration increases, there are
measurable levels of the xanthophyll metabolites that increase significantly during the
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supplementation period, table 7. Other carotenoids, including lycopene, a- and

P-

cryptoxanthin, a- and 0-carotene do not change significantly during the supplementation
period.

Table 7. Summary of serum carotenoids that experienced an increase in concentration
with supplementation
Baseline

Post-supplementation (nmol/dL)

(nmol/dL)

Placebo

Low Dose

metabolite 1

1.24 ±0.48

1.14 ±0.36

1.64 ± 0.67*

High Dose
2.74± 1.24**

metabolite 2

1.72 ±0.74

1.40 ±0.55

2.56± 1.05*

5.41 ±2.51**

metabolite 3

2.87 ± 1.04

2.34 ± 0.96

3.43 ± 1.27*

5.36 ± 2.25*

metabolite 4

1.39 ± 0.67

1.13 ±0.53

1.84 ±1.11*

2.10 ±1.15*

lutein

15.79 ±6.43

15.11 ±7.35

34.28 ±17.96*

71.41 ±35.98**

zeaxanthin

6.03 ± 2.80

5.03

1.77

8.03

2.70*

12.23 ± 5.85*

* Significant difference when compared to baseline concentration (p<0.05), ** p<0.001
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